Clinical Trials on Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

Total 7716 results

Hoffmann-La Roche

Completed

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

United States, France, Canada
University of Bonn
Pfizer; RWTH Aachen University; Ludwig-Maximilians - University of Munich; Heidelberg... and other collaborators

Unknown

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (BODO)

Chronic Myelogenous Leukaemia

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Immunex Corporation

Withdrawn

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
Versailles Hospital

Recruiting

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE | CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

France
Masonic Cancer Center, University of Minnesota

Completed

Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML

Relapsed Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML

Accelerated Phase Chronic Myelogenous Leukemia | Adult Acute Lymphoblastic Leukemia in Remission | Childhood Acute Lymphoblastic Leukemia in Remission | Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent... and other conditions

United States
Baylor Research Institute

Completed

Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS

Myelodysplastic Syndromes | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Dana-Farber Cancer Institute
Boston Children's Hospital; Brigham and Women's Hospital

Completed

Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia

Myelogenous Leukemia, Acute

United States
Cooperative Study Group A for Hematology

Completed

High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML (ADcomparison)

ACUTE MYELOGENOUS LEUKEMIA

Korea, Republic of
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
Therapeutic Advances in Childhood Leukemia Consortium
Genzyme, a Sanofi Company

Terminated

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Relapsed Acute Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Unspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditions

United States
University of Texas

Completed

Investigation of Clofarabine in Acute Leukemias

Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
Assistance Publique - Hôpitaux de Paris

Completed

5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS

Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukaemia (AML)

France
Hackensack Meridian Health

Terminated

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (FLUBUTBI)

Myeloproliferative Disorders | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myeloid Malignancies

United States
Wake Forest University Health Sciences

Completed

Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)

ACUTE MYELOGENOUS LEUKEMIA
Wake Forest University Health Sciences

Completed

Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)

ACUTE MYELOGENOUS LEUKEMIA
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Hematologic Diseases | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Novartis

Completed

PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Agnogenic Myeloid Metaplasia

United States
Masonic Cancer Center, University of Minnesota

Terminated

T-Cell Depleted Double UCB for Refractory AML

Acute Myelogenous Leukemia | Refractory Acute Myelogenous Leukemia

United States
Hoffmann-La Roche

Completed

A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.

Neoplasms, Myelogenous Leukemia, Acute

United States, Canada
National Cancer Institute (NCI)

Completed

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
S*BIO

Completed

A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies

Myelodysplastic Syndromes | Myelofibrosis | Chronic Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc; William Lawrence and Blanche Hughes Foundation

Active, not recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Relapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation

MDS | Chronic Lymphocytic Leukemia (CLL) | Acute Lymphoblastic Leukemia (ALL) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

United States
Center for International Blood and Marrow Transplant...
National Marrow Donor Program; Pediatric Blood and Marrow Transplant Consortium

Active, not recruiting

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Juvenile Myelomonocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Myelodysplasia | Acute Lymphoblastic Leukemia/Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Eisai Inc.

Terminated

Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects

Pediatric Acute Myelogenous Leukemia (AML)

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Stem Cell Transplantation for Patients With Cancers of the Blood

Acute Lymphocytic Leukemia | MDS (Myelodysplastic Syndrome) | CLL (Chronic Lymphocytic Leukemia) | CML (Chronic Myelogenous Leukemia) | AML (Acute Myelogenous Leukemia)

United States
AbbVie (prior sponsor, Abbott)

Completed

ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | B-cell Chronic Lymphocytic Leukemia | Myelodysplasia

United States
Masonic Cancer Center, University of Minnesota

Terminated

AHN-12 Biodistribution in Advanced Leukemia

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
University of California, San Francisco
American Society of Hematology

Completed

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
The University of Hong Kong

Unknown

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia

Leukemia, Myelogenous, Chronic Phase

Hong Kong
Merck Sharp & Dohme LLC

Terminated

Study of SCH 900776 (MK-8776) With and Without Cytarabine in Participants With Acute Leukemias (P05247)

Leukemia, Lymphocytic, Acute | Myelogenous Leukemia, Acute | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Myelogenous Leukemia, Chronic, Aggressive Phase
Center for International Blood and Marrow Transplant...
National Marrow Donor Program

Recruiting

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide (ACCESS)

Lymphoma | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Acute Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Mixed Phenotype Acute Leukemia

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Bio-Path Holdings, Inc.

Withdrawn

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia, Ph1-Positive

United States
National Cancer Institute (NCI)

Completed

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

United States
Merck Sharp & Dohme LLC

Terminated

Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649)

Acute Myelogenous Leukemia (AML)
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia

Chronic Myelomonocytic Leukemia | Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Terminated

Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation

Acute Lymphoblastic Leukemia | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia | Non-Hodgkins Lymphoma | Hodgkins Lymphoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Completed

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Assiut University

Unknown

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

Chronic Phase Chronic Myelogenous Leukemia

Clinical Trials on Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations